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Congenital afibrinogenemia is a rare bleeding disorder characterized by the absence in circulation of fibrino-
gen, a hexamer composed of two sets of three polypeptides (Aa, Bb and g). Each polypeptide is encoded by a
distinct gene, FGA, FGB and FGG, all three clustered in a region of 50 kb on 4q31. A subset of afibrinogen-
emia mutations has been shown to specifically impair fibrinogen secretion, but the underlying molecular
mechanisms remained to be elucidated. Here, we show that truncation of the seven most C-terminal residues
(R455–Q461) of the Bb chain specifically inhibits fibrinogen secretion. Expression of additional mutants and
structural modelling suggests that neither the last six residues nor R455 is crucial per se for secretion, but
prevent protein misfolding by protecting hydrophobic residues in the bC core. Immunofluorescence and
immuno-electron microscopy studies indicate that secretion-impaired mutants are retained in a pre-Golgi
compartment. In addition, expression of Bb, g and angiopoietin-2 chimeric molecules demonstrated that
the bC domain prevents the secretion of single chains and complexes, whereas the gC domain allows
their secretion. Our data provide new insight into the mechanisms accounting for the quality control of fibri-
nogen secretion and confirm that mutant fibrinogen retention is one of the pathological mechanisms respon-
sible for congenital afibrinogenemia.
INTRODUCTION
Congenital afibrinogenemia (OMIM 202400) is a rare autoso-
mal recessive disorder characterized by the complete absence
in circulation of fibrinogen, the precursor of fibrin, which is
the major protein of blood clots. Affected patients suffer
from various haemorrhagic manifestations during life: umbili-
cal cord haemorrhage is often the first sign of the disorder;
gum bleeding, epistaxis, menorrhagia, muscle haematoma
and haemarthrosis occur with varying intensity and spon-
taneous intracerebral bleeding or splenic rupture can occur
throughout life (1,2).
Fibrinogen is synthesized predominantly in hepatocytes
from two sets of three homologous polypeptide chains
(Aa, Bb and g), which assemble to form a 340 kDa hexameric
molecule [AaBbg]2, held together by 29 disulphide bonds.
The hexamer is characterized by a symmetrical structure,
with a central E domain connected by three-stranded coiled-
coils to two peripheral D domains. The D domains consist
of the globular C-terminus of the Bb (bC) and g chains
(gC) and of a portion of the coiled-coils (3). Both bC and
gC are members of the FReD (fibrinogen-related domain)
family (4). Each polypeptide is encoded by distinct genes,
FGA, FGB and FGG, clustered in a region of 50 kb on
human chromosome 4 (4q31). Since our identification of the
first causative mutation for congenital afibrinogenemia (5),
more than 40 mutations causing the disorder have been
described, all located in the fibrinogen gene cluster. The
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majority of these mutations are found in FGA and are null, i.e.
large deletions, frameshift, early-truncating nonsense or
splice-site mutations (6,7).
Mechanisms of fibrinogen assembly have been well studied.
During translocation of the single chains into the endoplasmic
reticulum (ER), a signal peptide is co-translationally cleaved
from each chain, and the 364Bb and 52g asparagine residues
are N-glycosylated. Assembly proceeds in the ER with the for-
mation of an [Aag] or [Bbg] intermediate. The addition of
either a Bb or an Aa chain gives rise to a [AaBbg] half-
molecule, which dimerizes to form the functional hexamer
(8). The protein undergoes several post-translational modifi-
cations in the Golgi complex, including maturation of
N-linked oligosaccharides, phosphorylation, hydroxylation,
sulfation (9). In contrast, fibrinogen secretion is not well
understood. As for other secreted proteins, fibrinogen
secretion is likely to be submitted to a quality control, but
so far, mechanisms controlling fibrinogen secretion are
unknown, although N-glycosylation and disulphide-bond
formation, which both occur during fibrinogen synthesis
(10–12), are known to play a crucial role in the proper
folding of membrane and secretory proteins in the ER.
Recently, the identification of several mutations has provided
insight into the domains putatively involved in the control of
secretion. The L353R, G400D (13), G414S (14), W437X (15)
and W437G (16) mutations, numbered according to the
mature protein, all localized in the Bb chain, were identified
in afibrinogenemic patients and studied in transfected COS
cells. In this model, expression of the mutant FGB cDNA, in
combination with normal FGA and FGG, demonstrated that
all five mutations had no effect on the intracellular assembly
of the hexamer, but inhibited its secretion into the medium.
Three other mutations in the bC domain, R255H (17),
D316Y (18) andW440X (19), were identified in heterozygosity
in patients with reduced fibrinogen levels. In these cases, the
mutant chain was not present in the circulating fibrinogen.
Altogether, these data strongly suggested that the bC domain
plays an important role in the control of fibrinogen secretion.
Okumura et al. (20) previously used serial C-terminal trun-
cations of the g chain to study the role of this chain in fibrino-
gen assembly and secretion. These authors demonstrated that
truncation of 25 residues from the C-terminus completely
abolished fibrinogen assembly. In this study, we used a
similar approach to investigate which residues of the bC
sequence are essential for hexamer secretion. We show that
removal of seven or more residues from the C-terminus of
the Bb chain leads to impairment of fibrinogen secretion.
Additional mutation analyses indicate that the six-amino
acid tail and the R455 residue may be important for secretion,
by preventing the exposure of hydrophobic amino acids
located within the bC domain. Using immunofluorescence
and immuno-electron microscopy, we demonstrate that
secretion-impaired mutants are retained in a pre-Golgi com-
partment. Finally, we generated and expressed chimeric
chains combining the N- and the C-termini of Bb and g
chains or angiopoietin-2 (Ang2). Our results show that pre-
sence of a bC domain is sufficient to inhibit the secretion of
chimeric chains or complexes, with the exception of the
native fibrinogen hexamer. In contrast, all gC-containing
chains or complexes are secreted effectively.
RESULTS
Deletion of at least seven amino acids from the Bb
C-terminus leads to inhibition of fibrinogen secretion
We previously identified a mutation in the fibrinogen Bb chain
(W437X) that, in transfected COS cells, specifically abolished
fibrinogen secretion into the medium (15). This mutation
resulted in the loss of 25 residues from the Bb C-terminus.
To determine how far in the primary sequence the amino
acids are essential for secretion, we generated FGB cDNA
mutants with serial truncations of the Bb C-terminus:
W440X (corresponding to the mutation identified in 19),
Y445X, K449X, K453X and F457X (Fig. 1A). When these
constructs were co-transfected in COS-7 cells with normal
FGA and FGG cDNAs, each Bb chain variant was expressed
(Fig. 1B, lysate, red) and did not impair fibrinogen assembly,
because the hexamer was detectable in the cell lysate (Fig 1B,
lysate, non-red). There is an apparent decrease in the ratio of
beta chain to gamma chain ratio as the extent of truncation
increases (Fig. 1B, lysate, red), suggesting greater instability
of these truncated chains. This is supported by the non-
reducing gel which shows a decrease in assembled hexamers
and [AaBbg] intermediates and a corresponding increase in
[Aag] intermediate.
On reduction of hexamers or assembled intermediates, Aa,
Bb and g chains (Fig. 1B, media, red) and hexamers (Fig. 1B,
media, non-red) were observed in the medium of cells trans-
fected with the wild-type (WT) FGB and the F457X mutant.
In contrast, when cells were transfected with the W440X,
Y445X, K449X, and K453X variants, no hexamers or Bb
chains could be detected in the medium, in which only
decreased amounts of Aa and g chains/complexes were
observed.
To refine this analysis, we co-expressed FGB constructs
carrying I454X, R455X or P456X mutations with normal
FGA and FGG (Fig. 1A). P456X did not abolish fibrinogen
assembly and secretion, whereas both I454X and R455X
impaired secretion (Fig. 1C). These experiments demonstrate
that the last six amino acids, from P456 to Q461, are dispen-
sable for fibrinogen secretion and that deletion of any
additional residue impairs this secretion.
Presence of either the six-residue tail or the R455
is required for fibrinogen secretion
To determine whether the nature of the six-residue tail was
important, we substituted it with six alanines. The resulting
P456_Q461(A)6 mutant (Fig. 2A) did not affect assembly or
secretion of fibrinogen (Fig. 2B), indicating that neither the
presence nor the nature of the C-terminal tail are crucial for
these two processes. To assess the intrinsic importance of
R455, we replaced it with an alanine. The R455A mutant
(Fig. 2A) was released as a hexamer (Fig. 2B), demonstrating
that the nature of amino acid 455 was again not critical for
fibrinogen secretion. In contrast, we found that a Bb mutant
carrying the R455A substitution in combination with the trun-
cation of the six most C-terminal amino acids
(R455Aþ P456X, Fig. 2A) was not secreted (Fig. 2B),
showing that R455 becomes critical for secretion in the
absence of the C-terminal tail.
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Secretion-impaired fibrinogen mutants are retained
in a pre-Golgi compartment
To determine where the secretion-impaired mutants were
retained, COS-7 cells were transiently co-transfected with
either WT FGA, FGG, FGB or normal FGA, FGG and one
of the three FGB secretion-impaired mutants, R455X,
W437X (15) and G414S (14), and immunostained for fibri-
nogen. As shown by confocal microscopy (Fig. 3A), both
WT and mutant fibrinogen molecules were localized in a
Figure 1. Serial truncations demonstrate that loss of seven or more residues from the Bb C-terminus inhibits fibrinogen secretion. (A) Sequences of normal and
mutated Bb chains are shown from residue G414. (B and C) Western blots of cell lysates and conditioned medium. COS-7 cells were co-transfected either with
the empty vector (2), normal FGA, FGG and FGB cDNAs (WT) or with the FGA, FGG and the indicated FGB mutant. Purified fibrinogen (Fg) was loaded as a
control. Samples were analysed by immunoblotting using anti-fibrinogen antibodies under reducing (red) or non-reducing (non-red) conditions. The positions of
Aa, Bb and g chains and of the [AaBbg]2 hexamer are indicated. Open arrowheads indicate fibrinogen intermediates, presumably the [AaBbg] half-molecules
and [Aag] molecules (8). Loading control was performed with anti-actin antibodies on reduced cell extracts. NB: the background signal for cells transfected with
the empty vector (cell lysate, red) is more intense in 1C than in 1B.
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perinuclear network pattern typical of ER. In addition, WT
fibrinogen co-localized with giantin, a Golgi marker, resulting
in a yellow merge signal. In contrast, none of the secretion-
impaired mutants co-localized with the Golgi marker.
Immuno-electron microsocopy revealed WT fibrinogen in
both the lamellae and the vesicles of the Golgi apparatus, as
well as in the cisternae of rough ER (Fig. 3Ba and b). In con-
trast, the R455X mutated form of the molecule was not immu-
nodetected in the Golgi apparatus, but was abundant in the ER
(Fig. 3Bc and d). These experiments show that the three
secretion-impaired fibrinogen mutants we analysed are
retained in a pre-Golgi compartment.
Presence of a bC domain causes retention of chimeric
chains or complexes, whereas a gC domain allows
their secretion
The bC and gC globular domains of the fibrinogen molecule
are 42% identical at the amino acid level (60% similar) and
are founding members of the FReD family (4). FReDs are
found in the C-terminus of proteins such as the fibrinogen
aE variant (21), angiopoietins (22–24), tenascins (25), ficolins
(26), fibroleukin (27) or Drosophila melanogaster scabrous
(28). Analysis of phylogenetic trees suggests a common ances-
tor for the various FReDs (29), and shows their high conserva-
tion from invertebrates to human, which underlines their
importance. So far, however, none of the FReDs has been
assigned a specific function, even though, to our knowledge,
all FReD-containing proteins multimerize and are secreted.
To investigate the role of the Bb and g FReDs in fibrinogen
secretion, we constructed chimeras (Fig. 4A) with the g
N-terminus fused with the bC (g–Bb mutant) domain, and
the Bb N-terminus fused with gC (Bb–g mutant). These
chimeras were transfected in COS cells either alone or in
combination with either Aa and Bb or Aa and g chains.
Both Bb–g and, in reduced amounts, g–Bb chimeras are
expressed in the cells (Fig. 4B, lysate, red). The much
fainter band of g–Bb may result from decreased stability.
Both chimeras were able to form a complex detected at
similar intensity, with an electrophoretic mobility comparable
to that of the fibrinogen hexamer (Fig. 4B, lysate, non-red).
This complex was found only when the g–Bb chimera was
co-transfected with Aa and Bb chains or when the Bb–g
chimera was co-expressed with Aa and g chains. These com-
binations are those in which the coiled-coil regions of all three
chains, known to be essential for fibrinogen hexamer assembly
(30), are preserved. In the medium, neither the g–Bb chimera
nor the hexameric [AaBbg–Bb] complex were detected,
suggesting that the fibrinogen molecule requires the presence
of a gC domain to be secreted. In contrast, the Bb–g chain
and the [AagBb–g] complex were both secreted in the
medium, indicating that the Bb N-terminus does not limit
secretion.
To further investigate the roles of the Bb and g FReDs, we
generated four other chimeras combining Bb or g fragments
and parts of Ang2, another FReD-containing protein
(Fig. 4A). The structure of Ang2 is very similar to that of
the Bb and g chains, as it contains a coiled-coil region,
and the Ang2 FReD shares .50% homology with the
Bb and g FReDs. Furthermore, the Ang2 FReD was recently
crystallized and its structure was shown to be superimposable
with the g FReD (31). All the chimeras we generated were
expressed in COS cells (Fig. 4C, lysate), with a higher
expression or stability of Ang2–g. Both Ang2–Bb and
Ang2–g chimeras were found to dimerize and further multi-
merize. In the medium, Ang2–g was abundant, Bb–Ang2
and g–Ang2 were easily and barely detected, respectively,
whereas Ang2–Bb was undetectable (Fig. 4C, media).
DISCUSSION
Congenital afibrinogenemia is mainly caused by null
mutations, i.e. large deletions, frameshift, early-truncating
nonsense or splice-site mutations (6,7). However, several
causative missense mutations have been recently described.
Among these, four mutations in FGB were shown to speci-
fically impair fibrinogen secretion (13,14,16) and in all
likelihood two others act in the same way (17,18). All six
mutations are localized in the bC domain (Fig. 5A) and are
predicted to destabilize its structure. In addition, two nonsense
mutations, W437X (15) and W440X (19), in this region
were also reported, removing 25 and 22 residues from the
Bb C-terminus, respectively. In this study, we investigated
which residues in the bC sequence are essential for hexamer
secretion. Using a COS cell model, we showed that removal
or substitution of the last six C-terminal amino acids, as
long as R455 is present, does not affect fibrinogen assembly
and secretion. In the bC domain, which features a central
Figure 2. Expression of Bb mutants show that the nature of the six-residue tail
and that of the R455 is not critical for fibrinogen secretion. (A) Sequences of
normal and mutated Bb chains shown from residue G442. Amino acid substi-
tutions are highlighted in bold. (B) Western blots on cell lysates or conditioned
medium were performed as described in Figure 1B and C.
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five-stranded b-sheet (Fig. 5A), the last five residues form a
highly flexible tail, and P456 ensures the transition between
the central b-sheet and the tail. The R455 position is stabilized
by six hydrogen bonds with three neighbours: F457, E309 and
G247 (Fig. 5B). Substitution of R455 by alanine disrupts at
least the hydrogen bonds formed by the arginine side chain,
i.e. one with E309 and two with G247. Under this condition,
secretion of fibrinogen was unaffected, indicating that these
bonds are not critical for this process. In the PDB structure
1FZA (3), R455, together with D241, E245, E309, E313,
H325 and K453, forms a closed sphere of mainly charged
amino acids, which presumably hinder solvent access to
W249, and thus to the hydrophobic core (Fig. 5C and D).
We postulate that the R455A substitution is of no consequence
for aqueous access to the core when the flexible C-terminal tail
is present. On mutation of R455 to alanine (Fig. 5E), one
building block of this protective barrier is replaced by a
small, hydrophobic residue. Because hydrophobic amino
acids in water minimize their surface by aggregating together,
we further hypothesize that the flexible tail collapses toward
A455 and that the terminal glutamines form the interface to
the solvent. In the absence of the tail, the R455A substitution
exposes the predominantly hydrophobic core to solvent, which
most likely leads to destabilization of the globular bC domain
(Fig. 5F). Accordingly, removal of the C-terminal tail as well
as R455 would further expose the core (Fig. 5G). These data,
together with the reported mutations in the bC region, strongly
suggest that fibrinogen secretion requires a proper folding of
the bC domain and is sensitive to subtle variations in the
distribution of hydrophobic and hydrophilic residues.
Figure 3. Secretion-impaired fibrinogen mutants are not found in the Golgi. (A) COS-7 cells co-transfected with either an empty vector or normal FGA, FGG,
FGB or FGA, FGG and a mutant FGB (R455X, W437X or G414S), were fixed, double-labelled with anti-fibrinogen (red) and anti-giantin (green) antibodies and
visualized by confocal microscopy. The images are representative of three independent experiments. Bar, 10 mm. (B) Immunolabelling of thin cryosections of
transfected COS-7 cells revealed WT fibrinogen in the Golgi apparatus (g) and rough ER (rer, a and b). In contrast, the R455X mutant was not detected in the
Golgi (c), but was abundant in the ER (c and d). Omission of the antibody against fibrinogen suppressed the aforementioned labelling (e), showing its specificity.
n, nucleus; bar, 300 nm.
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Previous studies in COS or HepG2 cells have attempted to
follow the transit of WT or mutant fibrinogen molecules
along the secretory pathway, using endoglycosidase H (endo
H) treatment (32–36). Endo H cleaves the high mannose
form of N-linked glycoproteins, found in the ER and the
cis-Golgi. In the medial-Golgi, proteins acquire a complex
oligosaccharide form, rendering them endo H-resistant.
These studies failed to detect endo H-resistant fibrinogen
molecules in cells, although one would expect to find some
fibrinogen in the Golgi. This may be explained by the fact
that intracellular fibrinogen molecules are predominantly in
the ER, as observed in our study (Fig. 3A) and that endo H
assays are not sensitive enough to detect the few high
mannose-containing fibrinogen forms. Only secreted fibrino-
gen molecules in cell media were found to be endo H resistant.
Here, by using immuno-electron microsocopy, we were able
to detect WT fibrinogen in the ER and the Golgi and demon-
strate that the three secretion-impaired mutants we analysed,
R455X, W437X (15) and G414S (14), failed to be targeted
to the Golgi compartment. Misfolding of many membrane or
secreted proteins, such as CFTR or a1-antitrypsin, leads to
their retention in the ER and to human disease (reviewed
in 37). Our results suggest that fibrinogen secretion-impaired
mutations lead to similar retention, thereby causing the
disease.
In an effort to specifically characterize the role of the Bb
and g FreDs on fibrinogen secretion, we studied chimeric
chains combining the N- and the C-termini of Bb and g
chains or Ang2. As summarized in Table 1, all chains (Bb,
g–Bb, Ang2–Bb) and complexes [AaBbg–Bb] containing
Figure 4. Expression of chimeric chains reveals a limiting role of the bC domain, not of the Bb N-terminus, and a positive role of the gC domain in secretion.
(A) Schematic representation of normal and chimeric chains combining Bb, g, or Ang2 half-proteins. Each segment is labelled by the number of the first and last
forming residue. (B and C) Western blots on cell lysates or conditioned medium were performed under the conditions indicated as in Figure 1. COS-7 cells were
transfected with Aa, Bb, g, Ang2 and/or chimeric cDNAs.
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the bC domain failed to be secreted, with the sole exception of
the native fibrinogen hexamer, suggesting that the Bb FReD
requires a suitable protein environment to be secreted. In con-
trast, chimeric chains or complexes with Bb N-terminus fused
to g or Ang2 FReD were secreted, demonstrating that the Bb
N-terminus does not limit secretion. Finally, gC-containing
chains (g, Bb–g, Ang2–g) and complexes [AagBb–g]
were abundantly secreted, whereas gC-lacking fibrinogen mol-
ecules [AaBbg–Bb] were retained within cells, revealing a
positive, if not essential role of aC in secretion. These
results are consistent with those of a study on chimeras com-
bining the N-terminus of the Drosophila FReD-containing
scabrous protein and human fibrinogen C-terminus (38). In
this case, scabrous-aE and -g were secreted, whereas scab-
rous-Bb was arrested in the secretory pathway. Moreover,
several studies on a variety of cells (including transfected
COS, CHO and BHK cells or Hep3B and HepG2 hepatoma
cells) have shown that single Aa and g chains and [Aag]
intermediates can be found in culture medium (8,15,33,39).
In all the cases, Bb chains were detected in conditioned
media only when incorporated in the full hexamer. Our
present results extend these observations by indicating that
the Bb chain cannot be secreted on its own, unlike Aa and
g chains, because of the limiting action of the bC domain.
In summary, our data show that the bC domain, not the Bb
N-terminus, limits secretion because it can be secreted only if
properly folded and incorporated in a suitable protein environ-
ment, provided by the two other fibrinogen chains. In contrast,
the g chain, specifically the gC domain, favours secretion.
Obviously, these conclusions, which derive from experiments
on COS-7 cells, may not be immediately extended to the
endogenous mechanisms of in vivo fibrinogen secretion by
hepatocytes. However, they are likely to summarize the
Figure 5. Structural analysis of the bC domain suggests that the six-residue tail and R455 prevent exposure of the bC core. (A) Localization of R455 (pink) and
of the missense mutations so far reported in Bb (blue). (B) Zoom on the R455 residue and its hydrogen bonds (green) shared with neighbouring amino acids. (C)
View on the charged sphere surrounding the non-polar W249. (D–G) Amino acids within a 10 A˚ radius of R455 in the (D) WT, (E) R455A, (F) R455Aþ P456X
and (G) R455X context. The secondary structures are highlighted: helix in green, b-strand in orange. For atom representation, acid residues were coloured in red,
basic in blue, polar in yellow and non-polar in grey. Figures were prepared using Swiss-PdbViewer and POV-Ray from the PDB file 1FZA (3).
Table 1. Secretion of Ang2, fibrinogen and chimeric proteins
Protein Secretion
Aa þ
Bb 2
g þþþ
[AaBbg]2 þþþ
g–Bb 2
Bb–g þþþ
[AaBbg–Bb] 2
[AaBb–g] þþ
Ang2–Bb 2
Bb–Ang2 þþ
Ang2–g þþþ
g–Ang2 þ
Chains and complexes were detected in culture medium with anti-fibrino-
gen antibodies. 2, undetected; þ, barely detected; þþ, detected; þþþ,
highly detected.
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central features of this control, as findings consistent with ours
have been made in various cell models or organisms.
Previous co-expression studies in COS-1 cells have shown
that Bb chains deleted of their C-terminal half (amino acids
208–461) could be secreted on their own and assembled
with Aa and g chains to form a secreted hexamer (40).
Together with our data, this observation favours a model in
which molecular chaperones recognize and retain, in a pre-
Golgi compartment, the fibrinogen molecules containing Bb
chains with misfolded bC domains. Hence, Bb chains that
lack the globular region may escape the quality control
machinery. Moreover, it is conceivable that some proteins
bind to the gC domain to favour its own secretion and that
of the fibrinogen hexamer. In this regard, two secretion-
impaired mutations recently identified in the g chain, G284R
(32,41) and W227C (42), might interfere with the positive
role of gC on secretion demonstrated here.
Interestingly, four chemically induced mutations (two of these
truncations in the FReD, two others uncharacterized) in the scab-
rous protein have been found to alter the intracellular location of
themolecule (43). TheWTproteinwas found in intracellular ves-
icles that underwent exocytosis, whereas the mutants were
retained within the cell in a perinuclear location, possibly corre-
sponding to the ER. All these data concur to indicate that struc-
tural defects in the FReDs limit the secretion, and especially
exit from the ER, of several proteins, in particular, fibrinogen.
In conclusion, our data provide new insight into the mech-
anisms accounting for the quality control of fibrinogen
secretion and demonstrate that mutant fibrinogen retention is
one of the pathological mechanisms responsible for congenital
afibrinogenemia.
MATERIAL AND METHODS
Plasmid constructs and site-directed mutagenesis
Human Ang2 cDNA was amplified by PCR from cDNAs of
HUVEC cells, using forward 50-GCTGCTGGTTTATTACT
GAAGAA-30 and reverse 50-TCAGGTGGACTGGGATGTT
TAG-30 oligonucleotides, and cloned into the pcDNA3.1/
V5-His-TOPO expression vector (Invitrogen), as were FGA,
FGB and FGG cDNAs (15). Insertion of mutations was per-
formed using the QuickChange Mutagenesis Kit (Stratagene),
with primers listed in Table 2. Throughout the text, mutations
and amino acids are numbered from the mature protein, i.e.
without the peptide signal. Addition of 19, 30 and 26 residues
corresponding to the signal peptides will yield the correspond-
ing amino acid number in the complete Aa, Bb and g chains,
respectively. For chimera generation, a BspEI restriction site
was inserted in FGB, FGG and Ang2 cDNAs. Then, for a
given X–Y chimera, the Y cDNA N-terminal part was
removed with Kpn I/BspEI digestion and gel purification.
The X cDNA N-terminal fragment was excised with Kpn I/
BspEI restriction and inserted in-frame into the digested Y
construct. All constructs had intact FReD domains (amino
acids 207–457, 149–389 and 280–494 for Bb, g and Ang2,
respectively; http://www.sanger.ac.uk/Software/Pfam/) and
fibrinogen intra-disulphide bonds and disrupted fibrinogen
C-terminal inter-disulphide bonds. The remaining free
cysteines in g-Bb (g C135) and Bb–g (Bb C193) were muta-
genized into serine residues. All PCR-based amplified and
mutated cDNAs were validated by sequencing.
Cell culture and transfection
COS-7 cells were grown in a humidified incubator at 378C and
5% CO2 in DMEM supplemented with 10% fetal serum and
penicillin/streptomycin. Cells were transiently transfected
with FuGENE6 reagent (Roche) according to the manufac-
turer’s instructions.
Western blot analysis
Cells and culture media were harvested, and western blots were
performed as previously described with minor modifications
Table 2. Oligonucleotide primers used for site-directed mutagenesis.
Template Mutation Oligonucleotide sequence (50 ! 30)
Bb R440X GTAGTATGGATGAATTAGAAGGGGTCATGG
Bb Y445X GGAAGGGGTCATGGTAATCAATGAGGAAG
Bb K449X GGTACTCAATGAGGTAGATGAGTATGAAGATC
Bb K453X GGAAGATGAGTATGTAGATCAGGCCCTTC
Bb I454X GATGAGTATGAAGTAGAGGCCCTTCTTCCC
Bb R455X GAGTATGAAGATCTGACCCTTCTTCCCAC
Bb P456X GTATGAAGATCAGGTAGTTCTTCCCACAGC
Bb F457X GAAGATCAGGCCCTAGTTCCCACAGCAATAG
Bb R455A GAGTATGAAGATCGCGCCCTTCTTCCCAC
Bb R455Aþ P456X GTATGAAGATCGCGTAGTTCTTCCCACAGC
Bb P456_F458(A)3 GAGTATGAAGATCAGGGCCGCCGCCCCACAGCAATAGAAGG
Bbþ P456_F458(A)3 P456_Q461(A)6 GATCAGGGCCGCCGCCGCAGCGGCATAGAAGGGCAATTCTG
Bb BspEI site GGAATATTGTCGCACCCCATCCGGAGTCAGTTGCAATATTCC
g BspEI site CAGTGCCAGGAACCTTCCGGAGACACGGTGCAAATC
Ang2 BspEI site CTGACTATGATGTCCGGATCAAACTCAGCTAAG
g-Bb C135S GCTTGAAGCACAGAGCCAGGAACCTTCC
Bb-g C193S CTCAAATGGAATATAGTCGCACCCCATCC
List of forward primers used in this study for site-directed mutagenesis. Mutated codons are shown in bold. W437X and G414S mutations were gen-
erated as previously described (14,15).
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(44). One day after transfection, cells were washed twice with
PBS and incubated for 24 h in serum-free medium. Con-
ditioned medium was concentrated using Amicon Ultra, 4
5 kDa (Millipore). Western blot analysis was performed
using polyclonal rabbit anti-human fibrinogen antibodies
(DakoCytomation) or mouse anti-actin IgG (Chemicon).
Immunofluorescence
Twenty-four hours after transfection, cells were fixed with 4%
PFA, permeabilized with 0.1% Triton X-100, blocked with 1%
bovine serum albumin (BSA), incubated for 1 h with primary
antibodies (anti-fibrinogen, 1:2000; mouse anti-giantin, 1:400,
Calbiochem) in 0.1% BSA and then for 45 min with goat
anti-rabbit and anti-mouse IgG conjugated to Alexa Fluor
568 and 488 (1:500, Molecular Probes), respectively. Images
were captured at room temperature with a LSM510 laser
scanning confocal microscope (Carl Zeiss), using a
Plan-Apochromat 63/1.4 oil objective. Three independent
experiments were performed.
Immuno-electron microscopy
Transfected cells were fixed for 5 min at room temperature in
either 4% PFA or 4% PFA plus 0.1% glutaraldehyde, followed
by a 60 min fixation in 4% PFA (all fixatives diluted in 0.1 M
phosphate buffer, pH 7.4). Cells were washed in 0.1 M phos-
phate buffer, embedded in 12% gelatin and cooled on ice.
Small blocs of cells were infused with 2.3 M sucrose, frozen
in liquid nitrogen and sectioned with an EMFCS cryoultrami-
crotome (Leica). Ultrathin sections were mounted on
parlodion-coated copper grids. The sections were processed
as in previously described protocols (45,46) which, in these
experiments, included a 1 h exposure to anti-fibrinogen anti-
bodies (1:100), and a 20 min exposure to 10 nm gold-
conjugated goat anti-rabbit IgG (1:10, BBInternational).
Cryosections were screened and photographed in a CM10
electron microscope (Philips). Negative controls, run by
exposing the sections to only the gold-conjugated goat anti-
bodies, resulted in a minimal, inconsistent staining of the
cells (Fig. 3Be). About 20 transfected cells, immunostained
above the minimal background labelling, were examined in
each group.
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